Kristi Kuhn, MD, PhD
In this video, Kristi Kuhn, MD, PhD, associate professor of rheumatology at University of Colorado Anschutz Medical Campus, discusses:
- introducing treatment options, like IL-17 inhibitors or JAK inhibitors, to patients;
- recent advances in biologics for nr-AxSpa, including certolizumab pegol (Cimzia, UCB), secukinumab (Cosentyx, Novartis) and ixekizumab (Taltz, Eli Lilly);
- supplementing treatment with physical therapy and moderate exercise to improve range of motion and reduce pain;
- a “critical limitation in knowledge:” understanding the length of nr-axSpA treatment if few patients will progress;
- a message to physicians to explore beyond an X-ray and diagnose with an MRI; and
- why clinical tests like HLA-B27 and X-rays should not be used to diagnose nr-AxSpa.